Literature DB >> 28372584

Long-term clinical outcome for patients poisoned by the fungal nephrotoxin orellanine.

Heidi Hedman1, Johan Holmdahl2, Johan Mölne3, Kerstin Ebefors4, Börje Haraldsson1, Jenny Nyström5.   

Abstract

BACKGROUND: Accidental intake of mushrooms of the Cortinarius species (deadly webcap) may cause irreversible renal damage and the need for dialysis or transplantation. The species is found in forests of Northern Europe, Scandinavia and North America and may be mistaken for other edible mushrooms. The highly selective nephrotoxic compound of the mushroom is called orellanine. Very little is known about the long-term effects of the nephrotoxin.
METHODS: We identified patients who ingested deadly webcap in the period of 1979 to 2012. Informed consent and medical records were obtained for 28 of the 39 cases that occurred during the 34-year period. A case control group was also studied based on sex, age and initiation of dialysis or transplantation.
RESULTS: The average age at time of the accidental intake was 40 ± 3 (n = 28) years. 64% of patients were male, and 22 of 28 patients developed acute kidney injury requiring dialysis. Serum creatinine peaked at 1 329 ± 133 μmol/l, and serum urea was 31 ± 3.5 mmol/l. No signs of acute damage were present in any other organ. The average time of follow-up was 16.9 ± 2.1 years (1.24-34.3 years, n = 28). 15 patients were transplanted and 3 also had a second graft. At follow-up, 23 patients were alive, and five had died at ages of 67 ± 5 (range 54-84). The outcome was similar in the case control group with 6 deaths in 20 patients.
CONCLUSION: We conclude that the long-term prognosis for patients poisoned by deadly webcap who lost their renal function is not different compared to other patients in active uremic care.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28372584      PMCID: PMC5379567          DOI: 10.1186/s12882-017-0533-6

Source DB:  PubMed          Journal:  BMC Nephrol        ISSN: 1471-2369            Impact factor:   2.388


Background

The mushroom known as the deadly webcap or Cortinarius rubellus (synonymous with Cortinarius speciosissimus) is occasionally mistaken for eatable chanterelles [1-5], Fig. 1. The habitats are unevenly distributed in Europe and North America and reports of poisoning episodes have been made from forestry areas throughout these regions. One to three of the deadly webcaps is considered enough to cause severe renal failure. There are usually no acute symptoms and the patient will seek medical advice 3 days to a week later with the symptomatology of uraemia caused by an acute kidney injury. The main symptoms of the uraemia at this stage are nausea and fatigue. Edema is less common due to an initial polyuric phase. This is in turn due to the tubulo-interstitial nephritis caused by damage to the tubular cells. In case of more severe poisoning, the patient becomes anuric after around 1 week [4].
Fig. 1

Specimens of the deadly webcap or Cortinarius rubellus (synonymous with Cortinarius speciosissimus), younger and older mushrooms with slightly different appearance. Picture by Hans Marklund

Specimens of the deadly webcap or Cortinarius rubellus (synonymous with Cortinarius speciosissimus), younger and older mushrooms with slightly different appearance. Picture by Hans Marklund The deadly webcap contains a highly selective nephrotoxin, orellanine, first described by Grzymala [6]. Orellanine (or [2, 2′-bipyridine]-3, 3′,4, 4′-tetrol-1, 1′-dioxide) is present in the mushroom in its basic form as a di-glycoside [7, 8]. The mechanism of action is that orellanine generates oxygen radicals [9-11] and simultaneously shuts down the oxidative defence, by down-regulating most anti-oxidative enzymes [9]. In rodents, the highly kidney-specific nature of orellanine has been verified. Thus, no acute symptoms have been observed at doses 1–2 orders of magnitude higher than the dose required to elicit acute renal failure [12, 13]. There are several case reports of the acute intoxication [1, 2, 14–18]. Due to the lag-phase between intake and symptoms, there are no signs of toxins in blood [19]. Suggested therapies during the years have been hemodialysis, hemoperfusion, corticosteroids and anti-oxidant therapies with highly varying and inconclusive results [4, 20, 21]. Regarding long-term effects of the intoxication, there are only a few reports following transplantation [17, 22]. There are no long-term follow up on patients after the initial acute kidney injury phase. Therefore, we tried to identify all cases of deadly webcap intoxication during the last three decades in the most affected (South-Western) region of Sweden and compared their outcome with a case-control group of patients. Our hypothesis was that the poison might have long-term effects or increase patient morbidity and mortality. Hence, a long time follow up of a patient cohort would be of interest.

Methods

Study population

We included all patients accidentally poisoned by intake of the mushroom deadly webcap (or Cortinarius rubellus, also known as Cortinarius speciosissimus) admitted to any of the hospitals in the Western part of Sweden during the period of January 1979 to December 2012. The total number of patients was 39. In this report, 28 patients were included based on informed consent and available medical records, see Table 1 for demographic data.
Table 1

Demographic data of the Cortinarius intoxicated patient cohort

Cont on dialysisGFRGFR YearAge at intoxAdmission YearCreaAlatAlpBilUreaAsatCancer
No.Biopsy(Y/N)† Year1st trpl Year2nd trpl YearInitial dialysisCKD5BPHbAlbInital peak values first w. after intoxicationafter intox
1a NNNN471979130/70116398890,223,659N
2a NNNN241979140/80149P 714000,192,990,33
3N1980YNY352011441979185/1001241550 0,3 3 6 37 0,3 Yb
4N1986YNY552012601985170/11095P 715420,544,17,5230,52Yc
5YYNN261985120/80861270 0,3 3 7 17 0,3 N
6a N19871999YNY382004211985
7Y19882003YNY1072009141987130/80101180024N
8N2012NNN401987130/80144P 671260,72,2110,47
9a NYYY261990
10NYYY161990
11N19922004YNY391991130/701233213330,4737,4450,23N
12N1992YNY411991130/801193210740,193,37,9340,17N
13N1992YNY211991135/801254514580,142,77,5420,24Yd
14N19991983YNY411979160/9014341163046
15N2000YYY681984180/95125P 72970 0,3 3 7 0,3
16N2000YNY282003281999
17N2001YNY522002271999
18N2002YNY4420123620011100 0,3 3 7 0,3 N
19N1995YYY40601984180/100111P 699700,262,214100,31
20Y2007YYY461999
21N2013YNY482007129/7110520,281,46,427,60,3N
22N2009YNY402009522007174/97N
23a NNNN252010160/1041152430,451,16
24Y2012YNY112012572010125/871273728090,1217,9N
25a NYYY612011145/809823130035
26NYYY392011150/801373010810,220,6250,47N
27a NNNN482011140/80152347100,61,36,925,20,72N
28a YNNN552012125/80152334730,511,58,2N

Patient data.a = no matched control available, F: female, M: male, TRPL: kidney transplantation, CKD: Chronic kidney disease, GFR: measured glomerular filtration rate, BP: blood pressure, Hb: hemoglobin value in g/L, Alb: serum albumin (in some cases protein was measured: P) g/L, Crea: creatinine in umol/L, Alat / Asat / ALP, values measured in μCat/L bilirubin (bil) measured in μmol/L. Liver values reported as normal was estimated (shown in italics). Yb: Oral cancer, Yc: Skin cancer, Yd: Hodgkins Lymphoma

Demographic data of the Cortinarius intoxicated patient cohort Patient data.a = no matched control available, F: female, M: male, TRPL: kidney transplantation, CKD: Chronic kidney disease, GFR: measured glomerular filtration rate, BP: blood pressure, Hb: hemoglobin value in g/L, Alb: serum albumin (in some cases protein was measured: P) g/L, Crea: creatinine in umol/L, Alat / Asat / ALP, values measured in μCat/L bilirubin (bil) measured in μmol/L. Liver values reported as normal was estimated (shown in italics). Yb: Oral cancer, Yc: Skin cancer, Yd: Hodgkins Lymphoma

Case control population

For each patient included in the study population that developed CKD5 (chronic kidney disease stage 5), we randomly included another patient as case control from the dialysis unit and another from the transplantation centre at Sahlgrenska University Hospital. Patients with diabetes or other systemic disease were excluded. The case controls were matched in age, sex, comorbidity and the year of the initiation of dialysis or transplantation. Such case control subjects could be found for all study patients in the dialysis group. However, three case controls are missing during certain years for the transplantation group due to large age differences. Most of the case control patients included had interstitial nephritis (75%), glomerulonephritis, or polycystic kidney disease, see Table 3 for demographic data.
Table 3

The table describes the demographic data available for the matched control cohortasecond transplant in 2003

A. Matched control patients who had hemodialysis
No#:Born yearTransplant 1DiagnosisFollow up MFollow up YDeath YCoDCancer
119351980PCK356302010PeritonitisY
219251986Amylioidosis9581994UnknownY
319652002Crescentic GN14112N
419532012IgAN202N
519582012PCK222N
619552009PCK595N
719421983Pyelonephritis36831
819721988a PCK30726N
919702000Interstitial Nephritis15613
1019732001IgAN19416
1119521992IgAN157132005EpilepsyN
1219511992Interstitial nephritis26322N
1319711992CGN26022
B. Matched control patients who had a renal transplantation
No#:Born yearHD startDiagnosisFollow up MFollow up YDeath YCoDCancer
1419251984CVD160131997CancerY
1519161984Heredetary nephropaty139121996Sepsis
1619621985Glomerulonephritis34329Y
1719421987CVD7261993CVD
1819651990Glomerulonephritis28424
1919521999Glomerulonephritis17815
2019732011Interstitial nephritis292N

aSecond transplant in 2003, M: months, Y: year, PCK:polycystic kidney disease, Crescentic GN: crescentic glomerulonephritis, IgAN: IgA nephritis, CGN: Chronic glomerulonephritis, CoD: cause of death, CVD: cardiovascular disease

The cohort was matched based on age, sex and A. initiation of hemodialysis or B. renal transplantation

Kidney morphology

Kidney biopsies were taken using gauge 16 needles, fixed in buffered paraformaldehyde, embedded in paraffin, sectioned and stained with standard dyes (haematoxylin-eosin, trichrome, silver and periodic acid-Schiff) and evaluated by a renal pathologist.

Statistical analysis

Results are presented as mean ± SEM (standard error of the mean). Differences between groups were calculated using the Gehan-Breslow-Wilcoxon test.

Results

Of the 39 patients identified, we were able to include 28 patients in the study. This was mainly due to difficulties to be able to get in contact and obtain an informed consent form from all patients. Of the 28 patients, 22 required dialysis initially, and 6 did not, Table 1. After 1 month, 21 patients had CKD5 requiring dialysis or transplantation and 7 patients had CKD stage 3. Thus, there was a 4.5% chance for a patient initially requiring dialysis to regain renal function during the first month after the intoxication (1/22). Of the 7 patients that were dialysis-free 1 month after the intoxication, all regained most of their renal function within the first year reaching CKD stage 1 or 2. For the total study population of 28 patients, the average time of follow-up was 16.9 ± 2.1 years (minimum 1.24 and maximum 34.3 years). 23 patients were alive at the time of follow up, but five had died at ages of 67.0 ± 5.1 years. Over the long observation period, three patients with end stage renal disease (ESRD) and hemodialysis died at the age of 70 ± 9 years after 11.9 ± 2.5 years on dialysis. One patient who never required dialysis died 24 years after the intoxication at the age of 65. Another patient died 19.1 years after the intoxication and 16 years after a successful kidney transplant at the age of 61. Fourteen patients were transplanted and of these three had a second kidney graft 12–15 years after the first one. The average age at the time of the accidental intake of poisonous mushrooms was 40 ± 3 years (n = 28), and 64% of patients were male. In the study group, 3 of the 16 transplanted patients developed cancer in the form of lymphoma, oral or skin cancer. Information of the specific cancer diagnosis was not available for the case control group.

Acute effects

The serum creatinine of the patients requiring dialysis peaked at 1 329 ± 133 μmol/l (n = 15) and serum urea reached 31 ± 3.5 mmol/l (n = 11). The peak creatinine and urea values were markedly lower in patients that did not require dialysis, Table 1. Laboratory tests did not show signs of damage in any other organ apart from the kidney. Thus, the aspartate amino transferase (ASAT), alanine amino transferase (ALAT), alkaline phosphatase (ALP) and bilirubin values were all within their normal limits in the patients analyzed; 0.35 ± 0,04 μCat/l, 0.34 ± 0.04 μCat/l, 2.38 ± 0.04 μCat/l, and 7.59 ± 0.5 μmol/l respectively (nALAT = 14, nASAT, ALP, bilirubin = 18).

Patients with non-dialysis dependent kidney injury

Six of the patients that were orellanine intoxicated developed a less severe kidney injury and never required dialysis. On average their serum creatinine peaked at 474 ± 117 μmol/l (n = 3) during the first week. Initially, two patients were treated with three sessions each of hemoperfusion with charcoal, which in 1979 was suggested as therapy. One patient initially required dialysis and had a serum creatinine of 1270 μmol/l, but regained part of her renal function within the first month, and had a glomerular filtration rate of 87 ml/min 1 year later determined by 51Cr-EDTA clearance. The 7 patients who did not develop CKD5 were followed over a time-period of 18.3 ± 5.8 years, range 1.2–34.3 years.

Patients with dialysis-dependent chronic kidney disease stage 5

One month after the intoxication, 21 of 22 patients still required dialysis. 14 of them were transplanted, 6 received a kidney graft from a living donor and 8 from a dead donor. Before transplantation, the patients had been on dialysis for 19 ± 4 months (range 7–64 months). Three renal grafts lost their function after 11, 12 and 15 years and a second kidney transplantation was performed. Those patients now have been living with their 2nd grafts for 10, 11 and 15 years, Table 1.

Kidney morphology

Kidney biopsies were obtained from 5/28 patients. The biopsy material from one patient could not be retrieved and thus material was available from 4 patients. According to clinical data biopsies were obtained 10–21 days after fungal ingestion. All biopsies showed a similar pattern dominated by acute tubular necrosis (ATN), Fig. 2. Two patients (no 5 and 28) showed less severe damage with focal involvement, while the other two biopsies (no 20 and 24) showed a diffuse involvement with generalized inflammation and tubular damage. These biopsies also showed tubular dilatation, tubular cellular atrophy and degeneration, Table 2. All biopsies contained some apoptotic bodies, interstitial edema and focal inflammation but no eosinophilia. Fibrosis was not a prominent finding.
Fig. 2

Light microscopy from a Cortinarius intoxicated patient showing proximal tubular damage (arrows) in some tubules. There are focal apoptotic bodies (arrowheads), denudation and tubular dilatation (★). Haematoxylin-eosin stain

Table 2

Renal morphology of biopsies from patients with Cortinarius poisoning

Patient No.Time after ingestionTubular damage: Necrosis, apoptosis, degeneration, dilatation, involvementEdemaInflammationFibrosis
52v0 + 0 0focalminimalminimalminimal
7--------
203v+ + + +diffusesevereprominentminimal
24>10d0 + + +diffuseprominentslightslight
2810d0 + 0 0focalfocalminimalminimal
Light microscopy from a Cortinarius intoxicated patient showing proximal tubular damage (arrows) in some tubules. There are focal apoptotic bodies (arrowheads), denudation and tubular dilatation (★). Haematoxylin-eosin stain Renal morphology of biopsies from patients with Cortinarius poisoning The case control patients were age and sex matched, and they started dialysis or were transplanted in the same year as the patients in the study population, Table 3. No acceptable case control could be found for three of the 16 transplanted study patients since the candidates were either too old or had systemic disease. The distribution of kidney disease within the population is displayed in Table 3. In total, 20 patients were matched, 7 of the patients were on dialysis and the remaining 13 patients were transplanted, one of them twice. Of the 20 patients, 6 died at a mean age of 67.5 ± 4.7 years after 16.9 ± 6.6 years on dialysis (n = 3, at a mean age of 68 years) and 10.3 ± 2.2 years after transplantation (n = 3, at a mean age of 66 year), Fig. 3. In the case control population, one patient died of cancer and three other patients developed tumours during the observation period.
Fig. 3

Kaplan Mayer survival curve over the two groups. No statistical differences were seen between the study group (intoxicated patients) and the control group over time

The table describes the demographic data available for the matched control cohortasecond transplant in 2003 aSecond transplant in 2003, M: months, Y: year, PCK:polycystic kidney disease, Crescentic GN: crescentic glomerulonephritis, IgAN: IgA nephritis, CGN: Chronic glomerulonephritis, CoD: cause of death, CVD: cardiovascular disease The cohort was matched based on age, sex and A. initiation of hemodialysis or B. renal transplantation Kaplan Mayer survival curve over the two groups. No statistical differences were seen between the study group (intoxicated patients) and the control group over time

Comparisons between study and control populations

Of the 21 patients with ESRD in the study group, 20 were matched; 7 in dialysis and 13 that were transplanted. Cancer was not more frequent in the study group compared to control group. There were 3 cases of cancer in the study population of 21 patients (14%), of which all 3 were transplanted. In the control group 3 out of 20 (15%) were diagnosed with cancer, two of which were transplanted and one which remained in dialysis. In total, 4 patients of 21 with ESRD died in the study group compared to 6 in the control group, see Fig. 3. There was no statistical difference between survivals in the study group compared to the case control group.

Discussion

The present study was done to reveal if patients that accidentally ingested deadly webcap (Cortinarius rubellus) suffered from long-term increases in morbidity or mortality. Indeed, 75% of the 28 patients developed CKD5, and 70% of them were transplanted. However, we did not find evidence of any other damage apart from the severe kidney injury. It should be noted that this is still a small patient group and of 39 cases we were only able to investigate 28 cases. Possible confounders could be the limited size of the study or that bias was introduced by co-morbidities or other medication. However, we do not anticipate that this has affected the outcome of the study. The follow up period after the accidental intake of poisonous webcap is quite long, 16.9 years, with a range of up to 34.3 years. As expected, the long-term survival was excellent after transplantation as reflected by the current follow up period of 19.0 ± 2.5 years for the 14 patients in that group. The result is in accordance with previous reports over shorter periods of follow up [17, 22]. Regarding dialysis, it is well known that the mortality is high for all age groups [23]. Naturally, the survival on dialysis will depend, not only on the dialysis practice, but also on the underlying disease and on comorbidities [23-25]. The outcome was quite good for the study population on dialysis, which so far has been followed for 12.4 ± 3.4 years. Some patients have died over the three and a half decades of follow up. However, the patients on dialysis died after more than 12 years of treatment with haemodialysis at a mean age of 68. A similar picture was found in the case control population with follow up periods for transplanted patients of 15.2 ± 2.8 years and of patients on dialysis for 14.4 ± 3.5 years. In the case control population there were three deaths in each of the two ESRD groups, with transplanted patients being 66 years at the time of death, and patients on dialysis being 68. We found no evidence of increased risk for malignancy, endocrinological disorders or other morbidity in the study population.

Conclusion

We conclude that the long-term outcome is equally good for patients that have lost their renal function due to accidental intake of deadly webcap compared to other reasons for the uraemia. This was true both for transplanted patients and patients treated with dialysis.
  22 in total

1.  Occurrence of the fungal toxin orellanine as a diglucoside and investigation of its biosynthesis.

Authors:  Peter Spiteller; Michael Spiteller; Wolfgang Steglich
Journal:  Angew Chem Int Ed Engl       Date:  2003-06-30       Impact factor: 15.336

2.  Irreversible renal damage from accidental mushroom poisoning.

Authors:  Nicholas Evans; Alexander Hamilton; Maria J Bello-Villalba; Coralie Bingham
Journal:  BMJ       Date:  2012-08-10

3.  Toxic properties of the mushroom Cortinarius orellanus. I. Chemical characterization of the main toxin of Cortinarius orellanus (Fries) and Cortinarius speciosissimus (Kühn & Romagn) and acute toxicity in mice.

Authors:  H Prast; E R Werner; W Pfaller; M Moser
Journal:  Arch Toxicol       Date:  1988-08       Impact factor: 5.153

4.  Acute renal failure after intoxication with Cortinarius mushrooms.

Authors:  J Holmdahl; H Mulec; J Ahlmén
Journal:  Hum Toxicol       Date:  1984-08

5.  Efficiency of haemoperfusion materials at removing the fungal toxin orellanine from human plasma.

Authors:  K Fulde; J Böhler; E Keller; A W Frahm
Journal:  Pharmazie       Date:  1998-01       Impact factor: 1.267

6.  Isolation of a lethal toxin from Cortinarius orellanus Fr.

Authors:  H Kürnsteiner; M Moser
Journal:  Mycopathologia       Date:  1981-05-08       Impact factor: 2.574

7.  The fungal nephrotoxin orellanine simultaneously increases oxidative stress and down-regulates cellular defenses.

Authors:  Ulf A Nilsson; Jenny Nyström; Lisa Buvall; Kerstin Ebefors; Anna Björnson-Granqvist; Johan Holmdahl; Börje Haraldsson
Journal:  Free Radic Biol Med       Date:  2008-01-31       Impact factor: 7.376

8.  Acute renal failure by ingestion of Cortinarius species confounded with psychoactive mushrooms: a case series and literature survey.

Authors:  H Frank; T Zilker; M Kirchmair; F Eyer; B Haberl; G Tuerkoglu-Raach; M Wessely; H-J Gröne; U Heemann
Journal:  Clin Nephrol       Date:  2009-05       Impact factor: 0.975

9.  Survival of elderly dialysis patients is predicted by both patient and practice characteristics.

Authors:  Celine Foote; Toshiharu Ninomiya; Martin Gallagher; Vlado Perkovic; Alan Cass; Stephen P McDonald; Meg Jardine
Journal:  Nephrol Dial Transplant       Date:  2012-05-07       Impact factor: 5.992

10.  Treatment of intoxication with Cortinarius speciosissimus using an antioxidant therapy.

Authors:  Markus Wörnle; Matthias W A Angstwurm; Thomas Sitter
Journal:  Am J Kidney Dis       Date:  2004-04       Impact factor: 8.860

View more
  4 in total

1.  Orellanine specifically targets renal clear cell carcinoma.

Authors:  Lisa Buvall; Heidi Hedman; Alina Khramova; Deman Najar; Lovisa Bergwall; Kerstin Ebefors; Carina Sihlbom; Sven Lundstam; Anders Herrmann; Hanna Wallentin; Emelie Roos; Ulf A Nilsson; Martin Johansson; Jan Törnell; Börje Haraldsson; Jenny Nyström
Journal:  Oncotarget       Date:  2017-07-25

2.  Pharmacokinetic Properties of the Nephrotoxin Orellanine in Rats.

Authors:  Deman Najar; Börje Haraldsson; Annika Thorsell; Carina Sihlbom; Jenny Nyström; Kerstin Ebefors
Journal:  Toxins (Basel)       Date:  2018-08-17       Impact factor: 4.546

Review 3.  Development and Validation of Indicators for Population Injury Surveillance in Hong Kong: Development and Usability Study.

Authors:  Keith T S Tung; Rosa S Wong; Frederick K Ho; Ko Ling Chan; Wilfred H S Wong; Hugo Leung; Ming Leung; Gilberto K K Leung; Chun Bong Chow; Patrick Ip
Journal:  JMIR Public Health Surveill       Date:  2022-08-18

4.  Demographic, clinical, and laboratory findings of mushroom-poisoned patients in Kermanshah province, west of Iran.

Authors:  Maryam Janatolmakan; Mohammad Rouhi Ganji; Touraj Ahmadi-Jouybari; Shahab Rezaeian; Mahnaz Ghowsi; Alireza Khatony
Journal:  BMC Pharmacol Toxicol       Date:  2022-09-26       Impact factor: 2.605

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.